San Antonio Breast Cancer Symposium 2025

 

Many Dana-Farber clinician scientists participated in the 2025 San Antonio Breast Cancer Symposium (SABCS), held December 9-12 in San Antonio Texas. This international symposium was directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as patient advocates and other appropriate health care professionals.

10,000 attendees from more than 100 countries attended this year. SABCS is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.   

Paolo Tarantino, MD discusses the DATO - Base study Video

Paolo Tarantino, MD discusses the DATO - Base study

Paolo Tarantino, MD, of Dana-Farber Cancer Institute, presented new findings from the DATO-Base study examining treatment with the ADC Dato-DXd for women with leptomeningeal disease. Breast cancer is the most common cancer linked to this ...
Erica Mayer, MD discusses results from TBCRC 56 study Video

Erica Mayer, MD discusses results from TBCRC 56 study

Erica Mayer, MD, of Dana-Farber Cancer Institute shared results from TBCRC 56, showing presurgical treatment with a PARP inhibitor + anti-PD1 combo in patients with gBRCAm early triple-negative breast cancer resulted in a pCR rate of 50%. ...
Erica Mayer, MD, MPH

Erica Mayer, MD, MPH

Medical Oncology
Ann Partride, MD discusses YES study Video

Ann Partride, MD discusses YES study

Breast cancer survivors who used a novel mobile health intervention to self-manage post-treatment symptoms were able to improve their quality of life and reduce the burden of common symptoms, according to results of the YES study presented ...
Ann Partridge, MD

Ann Partridge, MD

Medical Oncology
Rachel Freedman, MD discusses phase 2 ATOP study Video

Rachel Freedman, MD discusses phase 2 ATOP study

Dana-Farber Cancer Institute's Rachel Freedman, MD, presents results from the phase 2 ATOP study showing older patients with HER2+ breast cancer receiving adjuvant T-DM1 had a favorable 5-year survival with manageable toxicity. ATOP is ...
Rachel Freedman, MD

Rachel Freedman, MD

Medical Oncology
Stefania Morganti, MD discusses ctDNA study Video

Stefania Morganti, MD discusses ctDNA study

Ultrasensitive detection of minimal residual disease using ctDNA can help predict the duration of response to HER2 targeted therapy in patients with metastatic breast cancer, according to a study presented by Stefani Morganti, MD, of Dana-Farber ...

Additional Resources

 

Follow us on social media

 

Presentation and Poster Session Schedules